NL-OMON38130已完成3 期
A phase IIIb, open, multi-centre gynaecological extension study for the follow-up of a subset of HPV-015 study subjects - Gynaecological follow-up of a subset of HPV-015 study subjects
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 70
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •- A subjects previously enrolled in the HPV-015 study
- •- A subject with normal cervical cytology but positive test result for oncogenic HPV infection at concluding HPV-015 study visit
- •- A subject that was pregnant so that no cervical sample could be collected at concluding HPV-015 study visit
排除标准
- •- A subject with normal cervical cytology and negative test result for oncogenic HPV infection at concluding HPV-015 study visit
- •- A subject with a cervical lesion or with a cervical lesion that required treatment at concluding HPV-015 study visit
- •- A subject for whom the cervical cytology results were unavailable for reasons other than pregnancy at concluding HPV-015 study visit
研究者
相似试验
进行中（未招募）
1 期
A phase IIIb, open, multi-centre gynaecological extension study for the follow-up of a subset of HPV-015 study subjects - HPV-062 EXT:015GSK Biologicals' HPV-16/18 L1 VLP AS04 vaccine is indicated in females from 10 years of age onwards for the prevention of pre-malignant cervical lesions and cervical cancer causally related to Human Papillomavirus (HPV) types 16 and 18.EUCTR2009-017282-35-GBGlaxoSmithKline Biologicals34
进行中（未招募）
1 期
A phase IIIb, open, multi-centre gynaecological extension study for the follow-up of a subset of HPV-015 study subjects - HPV-062 EXT:015GSK Biologicals' HPV-16/18 L1 VLP AS04 vaccine is indicated in females from 10 years of age onwards for the prevention of pre-malignant cervical lesions and cervical cancer causally related to Human Papillomavirus (HPV) types 16 and 18.EUCTR2009-017282-35-PTGlaxoSmithKline Biologicals34
进行中（未招募）
1 期
Gynaecological follow-up of a subset of HPV-015 study subjectsGSK Biologicals' HPV-16/18 L1 VLP AS04 vaccine is indicated in females from 10 years of age onwards for the prevention of pre-malignant cervical lesions and cervical cancer causally related to Human Papillomavirus (HPV) types 16 and 18.MedDRA version: 14.1Level: LLTClassification code 10063001Term: Human papilloma virus infectionSystem Organ Class: 100000004862EUCTR2009-017282-35-NLGlaxoSmithKline Biologicals1,500
进行中（未招募）
不适用
A phase IIIb, open, multi centre gynaecological extension study for follow-up of a subset of 580299/008 study subjects who were either cervical cytology negative and oncogenic HPV positive or pregnant at their final 580299/008 study visit (Visit 10 at Month 48). - HPV-052 EXT 008GSK Biologicals’ HPV-16/18 L1 VLP AS04 vaccine is indicated in females from 10 years of age onwards for the prevention of cervical cancer (squamous-cell carcinoma and adenocarcinoma) by protecting against incident and persistent infections, cytological abnormalities including atypical squamous cells of undetermined significance (ASC-US) and cervical intraepithelial neoplasia (CIN), CIN1 and pre-cancerous lesions (CIN2 and CIN3), caused by oncogenic human papillomavirus (HPV) types 16 and 18.EUCTR2008-008124-33-FIGlaxoSmithKline Biologicals2,000
进行中（未招募）
不适用
Gynaecological follow-up of a subset of 580299/008 study subjectsGSK Biologicals’ HPV-16/18 L1 VLP AS04 vaccine is indicated in females from 10 years of age onwards for the prevention of cervical cancer (squamous-cell carcinoma and adenocarcinoma) by protecting against incident and persistent infections, cytological abnormalities including atypical squamous cells of undetermined significance (ASC-US) and cervical intraepithelial neoplasia (CIN), CIN1 and pre-cancerous lesions (CIN2 and CIN3), caused by oncogenic human papillomavirus (HPV) types 16 and 18.MedDRA version: 15.1Level: LLTClassification code 10063001Term: Human papilloma virus infectionSystem Organ Class: 100000004862EUCTR2008-008124-33-DEGlaxoSmithKline Biologicals2,000